BioCentury
ARTICLE | Company News

AstraZeneca sales and marketing update

June 27, 2016 7:00 AM UTC

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that added benefit of Tagrisso osimertinib from AstraZeneca is “not proven” vs. comparator th...